Apixaban Market - Size, Share, Outlook, and Forecast till 2026

Apixaban is an anticoagulant used to reduce blood clotting and risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is an oral factor Xa inhibitor and is sold under the trade name Eliquis. It was approved in Europe in 2012 and in the U.S. in 2014 for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban was developed in a joint venture by Pfizer and Bristol-Myers Squibb.

Increasing geriatric population and prevalence of atrial fibrillation in people over 80 years old are major factors that are expected to drive growth of apixaban market over the forecast period. Moreover, increasing incidences of deep vein thrombosis and pulmonary embolism is another factor boosting growth of apixaban market. Also, increasing investment in research and development activities in the pharmaceutical sector and launch of innovative oral anticoagulant drugs are fueling the market growth.

However, stringent regulations by governments and risk of side-effects and complications associated with the usage of oral anticoagulants is expected to hinder growth of the global apixaban market.

Key Developments in Apixaban Market

Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the apixaban market. On March 6, 2017, Bristol-Myers Squibb and Pfizer announced that they will present new analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session.

Bristol-Myers Squibb Company and Pfizer reported that they have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with Acute Coronary Syndrome (ACS) who were treated with apixaban or placebo in addition to mono or dual antiplatelet therapy. The study was stopped at an early stage based on the recommendation of an independent Data Monitoring Committee (DMC).

On December 5, 2017, Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia launched ‘Tune in to AFib, Take Note of Stroke Risk’ to educate the around seven million people in the U.S. in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke.

Some of the major players in the global apixaban market include Pfizer, Medichem, Polpharma, Beijing Cooperate Pharmaceutical, Centaur Pharmaceutical, DEAFARMA, and Dipharma Francis among others.

Global and Chinese Apixaban Industry, 2017 Market Research Report

Published Date : Oct 2017

The 'Global and Chinese Apixaban Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Apixaban industry with a focus on the Chinese market. The report provides key statistics on the market status of the Apixaban manufacturers and is a va...

Global Apixaban Market Research Report 2018

Published Date : May 2018

Apixaban Report by Material, Application, and Geography - Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, unit...

2017 Europe Apixaban Industry Report

Published Date : Nov 2017

This report is an essential reference for who looks for detailed information on Europe Apixaban market. The report covers data on Europe markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as Europe major vendors' information....

2017 India Apixaban Industry Report

Published Date : Nov 2017

This report is an essential reference for who looks for detailed information on India Apixaban market. The report covers data on India markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as India major vendors' information....

2017 Japan Apixaban Industry Report

Published Date : Nov 2017

This report is an essential reference for who looks for detailed information on Japan Apixaban market. The report covers data on Japan markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as Japan major vendors' information....

2017 US Apixaban Industry Report

Published Date : Nov 2017

This report is an essential reference for who looks for detailed information on US Apixaban market. The report covers data on US and its regional markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as US major vendors' informat...

2017 China Apixaban Industry Report

Published Date : Nov 2017

This report is an essential reference for who looks for detailed information on China Apixaban market. The report covers data on China and its regional markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as China major vendors'...

 

Select License :

  • Single User : $4500
  • Multiple User : $7000
  • Corporate User : $10000

Happy To Assist You

Assist you at Worldwide Market Reports

We will be happy to help you find what you need. Please call us or write to us:

Worldwide Market Reports Benefits

Custom Research Solution

Talk to our research consultant to design an exclusive report as per your research needs.

Customer Fulfilment

We aim to fulfil client's research demands with tailored research solutions.

Quick Turnaround Time Reports

We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

360-degree Approach

We cover each industry from supply and demand side with an aim to provide a most holistic research study.